Biohaven Ltd. (BHVN): R&D Expense
$635.07M
Year ended 2025-12-31
$467.75M
Trailing 12 months to 2026-06-30
+13.3%
3-year compound annual growth
+45.2%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $635.07M | -20.2% | 2026-03-02, From 2025-01-01 |
| 2024-12-31 | $795.87M | +113.2% | 2026-03-02, From 2024-01-01 |
| 2023-12-31 | $373.28M | -14.6% | 2026-03-02, From 2023-01-01 |
| 2022-12-31 | $437.07M | +140.8% | 2025-03-03, From 2022-01-01 |
| 2021-12-31 | $181.49M | +84.3% | 2024-02-29, From 2021-01-01 |
| 2020-12-31 | $98.46M | n/a | 2023-03-23, From 2020-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Biohaven Ltd. (BHVN) | 2025-12-31 | $635.07M | -20.2% |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | 2025-12-31 | $121.20M | +65.8% |
| BGM Group Ltd. (BGM) | 2025-09-30 | $672.7K | -50.6% |
| Arcutis Biotherapeutics, Inc. (ARQT) | 2025-12-31 | $77.05M | +0.8% |
| Bicara Therapeutics Inc. (BCAX) | 2024-12-31 | $63.60M | +107.8% |
| Enliven Therapeutics, Inc. (ELVN) | 2025-12-31 | $85.86M | +6.3% |
| MapLight Therapeutics, Inc. (MPLT) | 2025-12-31 | $138.35M | +101.9% |
| MoonLake Immunotherapeutics (MLTX) | 2025-12-31 | $202.86M | +79.9% |
| Rhythm Pharmaceuticals, Inc. (RYTM) | 2025-12-31 | $167.34M | -29.7% |
Compare BHVN, BBOT, BGM, ARQT side by side · Screen every company in Pharmaceutical Preparations ↗